The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 20, n. 1, 2019. DOI: 10.7175/fe.v20i1.1435. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1435. Acesso em: 29 oct. 2025.